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Abstract
Influenza remains a significant cause of disease mortality. The ongoing threat of influenza infection is partly
attributable to the emergence of new mutations in the influenza genome. Among the influenza viral gene
products, the hemagglutinin (HA) glycoprotein plays a critical role in influenza pathogenesis, is the target for
vaccines and accumulates new mutations that may alter the efficacy of immunization. To study the emergence
of HA mutations during the course of infection, we employed a deep-targeted sequencing method. We used
samples from 17 patients with active H1N1 or H3N2 influenza infections. These patients were not treated
with antivirals. In addition, we had samples from five patients who were analyzed longitudinally. Thus, we
determined the quantitative changes in the fractional representation of HA mutations during the course of
infection. Across individuals in the study, a series of novel HA mutations directly altered the HA coding
sequence were identified. Serial viral sampling revealed HA mutations that either were stable, expanded or
were reduced in representation during the course of the infection. Overall, we demonstrated the emergence of
unique mutations specific to an infected individual and temporal genetic variation during infection.
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Emergence of Hemagglutinin 
Mutations During the Course of 
Influenza Infection
Anna Cushing1, Amanda Kamali2, Mark Winters3, Erik S. Hopmans1, John M. Bell1, 
Susan M. Grimes1, Li C. Xia4, Nancy R. Zhang5, Ronald B. Moss6, Mark Holodniy2,3 & 
Hanlee P. Ji1,4
Influenza remains a significant cause of disease mortality. The ongoing threat of influenza infection 
is partly attributable to the emergence of new mutations in the influenza genome. Among the 
influenza viral gene products, the hemagglutinin (HA) glycoprotein plays a critical role in influenza 
pathogenesis, is the target for vaccines and accumulates new mutations that may alter the efficacy 
of immunization. To study the emergence of HA mutations during the course of infection, we 
employed a deep-targeted sequencing method. We used samples from 17 patients with active H1N1 
or H3N2 influenza infections. These patients were not treated with antivirals. In addition, we had 
samples from five patients who were analyzed longitudinally. Thus, we determined the quantitative 
changes in the fractional representation of HA mutations during the course of infection. Across 
individuals in the study, a series of novel HA mutations directly altered the HA coding sequence 
were identified. Serial viral sampling revealed HA mutations that either were stable, expanded or 
were reduced in representation during the course of the infection. Overall, we demonstrated the 
emergence of unique mutations specific to an infected individual and temporal genetic variation 
during infection.
Influenza infection is a major cause of mortality worldwide1. Two influenza subtypes, A and B, cause 
the majority of infections. Influenza A’s viral genome has eight genes that encode 11 different proteins 
including hemagglutinin (HA) and neuraminidase (NA) glycoproteins. The HA glycoprotein targets the 
sialic acid residues on host respiratory epithelium and plays a critical role in influenza pathogenesis. 
Currently, there are 18 known HA types (i.e. H1, H2, etc.) with the majority of infections caused by H1 
and H3. Within the HA protein are a number of residues which are antigenic sites - both H1 and H3 
have at least five different epitopes that are know to be immunogenic2,3. It is these antigenic sites that 
serve as the targets for current influenza vaccine.
De novo mutations and other genetic variation is introduced into influenza’s genome via a number 
of mechanisms and they may have significant clinical consequences4. On a population level, antigenic 
drift is the result of new mutations that are introduced into currently circulating strains over time, while 
antigenic shift occurs when genetic segments are mixed with novel components, sometimes between 
species. Antigenic drift is attributable to influenza’s low fidelity RNA polymerase that lacks a function for 
error proof-reading. With each replication cycle, polymerase errors create de novo mutations, increasing 
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the genetic diversity of the virus. As a result, mutations can occur in the HA gene5–7 and depending on 
their position, potentially alter HA’s antigenic epitopes.
Within a single infected individual, there are viral subpopulations or quasispecies characterized by 
novel mutations within various influenza genes such as HA5–7. We developed a robust and accurate next 
generation sequencing (NGS) approach to quantitatively detect new HA mutations and their representa-
tion in the overall viral population in an infected individual (Fig. 1)8. Using an Illumina sequencer, we 
readily generate ultradeep sequencing coverage greater than 10,000× from target genes (Flaherty et al., 
Nucleic Acids Research, 40, 2012)8. To improve the sensitivity and specificity of detection of mutation 
even at very low allelic fractions that are representative of small quasispecies populations (e.g. less than 
1.0%), we developed a Beta-Binomial statistical algorithm. This analysis method takes into account 
experimental variance from the molecular preparative assay (e.g. amplification, duplicated reads, etc.) 
and sequencing errors8. We minimize false positives in the variant calling and as a result, accurately 
determine the quantitative mutation allelic fraction (MAF) of a true mutation from experimental sam-
ples8. In a previous report, we used this methodology to accurately identify low abundance mutations in 
the NA gene among infected individuals.
For this study, we sought to characterize quantitatively mutations in the HA gene from a larger group 
of patients with H1N1 or H3N2 influenza infection. Our study had two goals. First, we sought to identify 
the presence of HA mutations that are present at a low fraction within the overall viral population pres-
ent in an infected individual. These rare HA mutations are representative of new quasispecies within an 
infected individual and may have clinical implications for vaccines. Second, in a subset of these patients 
we determined the temporal variation in HA mutations using samples obtained at two separate time 
points from the same individual. During the course of an infection, temporal changes in these mutations 
representation provide insight about the possible origin of antigenic drift.
Results
Viral samples and their characteristics. A total of 17 subjects were involved in the study with 
confirmed H1N1 or H3N2 infection as determined with quantitative PCR specific to each subtype of the 
HA gene (Table 1). Subjects were otherwise healthy individuals. Seven patients had H1N1 infection and 
10 patients had H3N2 infection. None of the individuals in this study received antiviral therapy and all 
of them recovered spontaneously. The age range was from 19 to 56 years with an average of 36.1 years. 
Nine subjects were men and eight were women.
The subjects presented with influenza-like illness (ILI) with an oral temperature of ≥ 100 °F ( ≥ 37.8 °C) 
and have one or more ILI symptom (cough, sore throat, nasal symptoms, headache, myalgia, sweat/chills, 
or prostration). Thus, samples listed as Day 1 represents the first sample taken from subjects in the 
study from which they were initially recruited (Table 1). Nasopharyngeal samples were obtained within 
48 hours of symptom onset. H1N1 and H3N2 presence and viral loads (i.e. RNA copies/mL) were deter-
mined from the same quantitative HA PCR testing used for viral typing; sample viral load ranged from 
7.2 × 10E5 to 1.18 × 10E8 copies/ml (Table 1).
Based on the viral load, we determined the viral copy number present in each sample. Those samples 
with low viral loads have a limited number of viral copies. With PCR amplification, starting with a low 
number of viral copies may lead to artifactual mutations. To reduce the possibility of spurious mutations 
as a result of PCR amplification error and bias, we used samples that had greater than 1.00 × 10E5 viral 
copies per amplification reaction. Per our calculations as detailed in the Methods, this viral copy number 
provides an adequate number of template molecules for detecting mutations at a MAF of 0.5% with high 
sensitivity and specificity. In addition, a subset of patients had viral samples collected longitudinally after 
the initial diagnosis (Table 1). This follow up sample was collected on either Day 3 or 5 during the course 
Figure 1. HA mutation analysis approach. Clinical HA samples were sequenced alongside three technical 
replicates of a control sample with known sequence. Sequence alignment was conducted. The rare variant 
detection method, RVD, was applied to sequencing output BAM files to call mutations using a minimum 
threshold of 0.5% mutation allele frequency (MAF).
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of active infection from one H1N1 patient and four H3N2 patients. They had adequate viral copy number 
for additional sequencing analysis.
Overview of deep sequencing of the H1N1 and H3N2 HA gene. Our sequencing analysis of the 
HA gene included a series of control replicates that were run in parallel with the experimental samples 
(Fig.  1). We used either a H1N1 or H3N2 HA gene amplicon that was subcloned into a plasmid; this 
was the starting template for the control replicates. The plasmid was colony purified to insure a clonal 
version was used in all experiments. Run in triplicate, this control enabled us to determine the extent of 
artifact mutations introduced from sequencing library preparation.
For sequencing, we relied on a PCR primer pair that produces a 1.6 Kb amplicon spanning the entire 
HA gene. We used a random insert transposase method for generation of the sequencing libraries. Direct 
amplicon sequencing was not practical because the size of the HA gene; this would require multiple PCR 
pairs which would significantly complicate the sequencing process and analysis. HA sequencing libraries 
were run on an Illumina MiSeq with 150 base paired-end reads. For alignment, we used the program 
BWA with HA references specific to one or the other subtype.
High sensitivity HA mutation calling. The samples underwent sequencing on an Illumina MiSeq 
with 150 × 150 paired end reads. All the samples exceeded 10,000× average coverage with one exception; 
this sample had 9,077× average coverage. On the aligned sequence data, we used the RVD program9 
for quantitative detection of mutations at low allelic fraction. As noted previously RVD relies on the 
sequence data from the control replicate to characterize a position specific error distribution. It models 
the error that may occur from different steps of the sequencing process (e.g. PCR amplification, library 
preparation, sequencing errors)8. Processing the control amplicon replicates and sample sequencing data 
simultaneously, RVD estimates the context-specific error at each base position for any given target gene8. 
This includes the wildtype “reference” reads versus the variant-containing “non-reference” reads and 
fits the model to the control replicate data. For example, setting the threshold p-value at α = 1 × 10−6 
is equivalent to a Bonferroni corrected level of α = 1 × 10−3 for a 1 Kb target region and thus has a low 
false positive rate after controlling for multiple hypothesis testing.
Influenza 
Subtype
Patient 
Identifier
Age 
(years) Gender
Day of 
Sample*
Viral Loadǂ 
(copies/ml)
Viral Load 
Log 10 
(copies/ml)
H1N1
325002 31 F 1 6.056E + 06 6.782
326002 23 F 1 1.653E + 06 6.218
328011 42 M 1 5.535E + 06 6.743
3 7.199E + 05 5.857
335007 19 M 1 2.761E + 06 6.441
343011 56 F 1 1.181E + 07 7.072
350002 38 M 1 3.463E + 06 6.539
350006 30 F 1 1.712E + 06 6.234
H3N2
302004 42 M 1 1.257E + 07 7.099
302010 32 M 1 9.561E + 05 5.981
3 1.081E + 06 6.034
302012 32 M 1 1.114E + 08 8.047
3 3.370E + 06 6.528
302014 23 M 1 3.754E + 06 6.574
5 1.705E + 06 6.232
317002 37 F 1 1.184E + 08 8.073
3 2.217E + 07 7.346
332005 39 F 1 4.703E + 07 7.672
332009 55 M 1 2.484E + 07 7.395
348007 47 F 1 3.605E + 06 6.557
348020 44 F 1 7.238E + 06 6.860
349002 23 M 1 4.213E + 06 6.625
Table 1. Influenza sample characteristics. *Day 1 is defined as the first day a sample was collected and was 
required to be collected within 48 hours of symptom onset. ǂ The influenza hemagglutinin gene was used as 
a PCR target to determine influenza viral load copy number.
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With RVD, we determined the sensitivity and specificity of deep sequencing in detecting low abun-
dance mutations. From our previous study (Flaherty et al., 2012), we generated a receiver operator curve 
(ROC). We demonstrated that with an average sequencing coverage of 10,000× , one has excellent power 
at a significantly low false positive rate to discriminate a variant fraction of 0.5%8. Even higher sensitivity 
at a MAF threshold of 0.1% is achievable although our previous studies have demonstrated a drop in 
specificity. Therefore, we relied on a 0.5% MAF threshold that provides a high specificity greater than 
95%.
Reproducibility of HA mutation detection. To determine the reproducibility of quantitative muta-
tion calling, we studied the effect of different steps in the sequencing library preparation. First, we exam-
ined the effect of PCR amplification on the sensitive detection of variants above the 0.5% threshold. 
For this experiment, we generated independent replicates with amplified HA products from the same 
viral sample (e.g. Patient 328011 with H1N1 infection). After library preparation, the independent rep-
licates were sequenced and aligned to the HA reference. We achieved an average sequencing coverage of 
34,000× on both samples and the sequence data was analyzed with RVD. Both replicates had a total of 
five common mutations at a MAF of 0.5% or higher. We compared the MAF values for each mutation 
as shown on a scatterplot (Fig.  2a) and demonstrated a correlation coefficient of greater than 0.999. 
Around the threshold of 0.5%, two mutations were found above 0.5% in one sample but slightly below 
0.5% (0.47%) in the other.
We also determined the contribution of reverse transcription on mutation calling reproducibility. 
Using the same H1N1 viral RNA from patient 328011, we prepared independent experimental replicates 
starting with the reverse transcription step followed by amplification of the HA gene. Post-sequencing, 
we achieved an average sequencing coverage of 34,000× for two independent replicates. Like the PCR 
replicates, we identified the same five mutations between the two reverse transcription replicates. 
Figure 2b shows the mutation MAFs from the replicates in a scatter plot and again we demonstrated a 
high correlation coefficient of greater than 0.999. Overall, this analysis indicates the reproducibility of 
our mutation detection and MAF quantitative measurements.
Deep sequencing the HA genes from individuals with H1N1 or H3N2 infection. We deter-
mined the number of viral copies required for accurate detection of mutations, using our MAF detection 
threshold of 0.5% (Methods). For example, if the library preparation uses a sample with 1,000 viral tem-
plates, accurate detection of a mutation with MAF of 0.1% would require amplification of a single mutant 
allele molecule. Overall, low viral copies per PCR amplification increases the likelihood of amplification 
bias and introducing PCR related artifacts. Based on our calculations using the viral loads of the samples, 
when one uses 1.0 × 10E5 viral templates or greater for each PCR amplification of the HA gene there is 
less chance of introducing of spurious mutations.
For any given sequencing run, three HA control replicates were run for either the H1N1 or H3N2 
subtypes in parallel with the clinical samples. Data was generated using four separate sequencing runs. 
The sequence data was aligned to the HA reference specific to each subtype (See Methods). For all sam-
ples, the sequencing metrics are provided in Supplementary Table 1. Sequence data quality was high with 
88% to 99% of the total number of sequence reads had base quality scores greater than 30. Alignment 
to the HA gene was greater than 88% of the reads and the average number of aligning reads for the 
Figure 2. Mutation reproducibility demonstrated in independent experimental replicates. The 
reproducibility of quantitative mutation detection was determined with a series of independent experimental 
replicates. The effects of (a) PCR amplification and (b) reverse transcription were evaluated. An inclusive 
0.5% fractional cutoff was used and all mutations found in one of the sample replicates were considered 
simultaneously. The correlation coefficient for each comparison was calculated and the best-fit slope was 
plotted.
www.nature.com/scientificreports/
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H1N1 samples was 576,203 and for the H3N2 samples was 492,590. For the H1N1 samples, the average 
sequencing coverage ranged from 27,343× to 61,301× . For the H3N2 samples, the average sequencing 
coverage distribution ranged from a low of 9,077× to a high of 73,276× . Overall, the individual viral 
samples yielded high quality sequence data. All of the sequence data is available at the NIH Short Read 
Archive (SRA) with the accession identifier SRP051062.
HA mutations and MAF quantitation from deep sequencing of H1N1 and H3N2 infec-
tions. Post-alignment, we conducted RVD analysis and identified HA mutations with a MAF greater 
than 0.5% (Supplementary Tables 2 and 3). A summary of the H1N1 and H3N2 HA mutation charac-
teristics are presented in Table 2. From a total of 17 patients, 15 individuals had a HA mutation detected 
at a 0.5% MAF or greater in their influenza sample.
From the 22 influenza samples, we identified a total of 40 mutations of which 38 were unique. There 
were 35 unique SNVs and 3 deletions with sizes ranging from 1 to 5 bases. The quantitative allelic frac-
tion (e.g. MAF) of the H1N1 and H3N2 HA mutations ranged from 0.50 to 66.00%. Among the H1N1 
and H3N2 viral samples, all of the HA mutations were exclusive to a given patient.
As noted in the Methods, we determined the consensus sequence of the HA gene for each sample 
using the information available at the Influenza Research Database (http://www.fludb.org). Afterwards, 
we used PhyML10,11 to generate phylogenetic trees across the clinical samples (Fig. 3). The H1N1 samples 
were closest to the A/Springfield/INS5598/2011 isolate (Genbank CY129862.1). The H3N2 samples were 
closest to the A/Tennessee/F2059/2011 isolate (Genbank CY167636.1).
The only example of duplicated mutations occurred in longitudinal samples originating from the 
same individual (Patients 302014 and 317002) but at different time points. Overall, each mutation was 
unique to the viral population for any given patient. In addition, these results indicate that there was no 
inter-sample contamination or carryover that would lead to common mutations appearing.
Influenza Subtype H1N1 H3N2
Total Number of Unique HA Mutations 16 22
HA Nonsynonymous Mutations 8 11
Predicted Deleterious HA Mutations 3 5
Average HA Mutations Per Sample 2.0 1.6
Total Number of Viral Samples 8 14
Viral Samples with HA Mutations > 0.5% 
MAF 7 10
Viral Samples with Nonsynonymous 
Mutations 6 7
Table 2.  Summary of HA mutations.
Figure 3. Phylogenetic trees comparing H1N1 and H3N2 clinical samples to known sequences. 
Phylogenies demonstrate the variation in sequence across the (a) H1N1 and (b) H3N2 clinical sample 
compared to the amplicon HA control sample sequences (A/USA/RVD_H1/2011_H1N1 and A/USA/
RVD_H3/2011_H3N2) and the closest independent sequence isolate by BLAST search (A/Springfield/
INS5598/2011 and A/Tennessee/F2059/2011). The scale bar indicates number of substitutions per nucleotide. 
Phylogenies were created using phylogenetic tree tools available at fludb.org.
www.nature.com/scientificreports/
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We evaluated the fractional representation of the mutations at the time of Day 1. For H1N1 HA muta-
tions, 68% (16/17) of the mutations had a MAF of less than 2%. Similarly for the H3N2 HA mutations, 
70.5% (12/17) of the mutations had a MAF of less than 2%. These results suggest the emergence of de 
novo mutations, indicated by very low MAFs, during infection.
Several patients with H1N1 or H3N2 infection had mutations at a MAF greater than 10%. Three H1N1 
patients (328011, 335007 and 35002) had mutations present that ranged from 19.60% to 32.90%. Four 
H3N2 patients had either nonsynonymous, synonymous or deletion mutations ranging from 11.70% to 
61.10%. Infections that have mutations with higher MAF values may be indicative of mixed infections 
where the individual host has been infected with multiple viral variants6.
Among the 38 missense mutations, 19 altered the amino acid composition of the HA gene (Table 2; 
Fig. 4). For H1N1, there were eight nonsynonymous mutations leading to amino acid substitutions. For 
H3N2, there were 11 nonsynonymous mutations leading to amino acid substitutions. To determine the 
potential functional consequences of the amino acid substitutions, we used the program PROVEAN12. 
This program determines the degree of amino acid conservation compared to other sequences and pro-
vides a score for the impact of the variant on protein function. It has been used for interpreting the 
impact of amino acid substitutions in influenza genes. A score of less than − 2.5 indicates a high proba-
bility of deleterious changes to the protein’s function. We also considered the amino acid position of the 
mutation compared to HA domains that have been previously characterized.
For the H1N1 results, three missense mutations were predicted to have a significant impact on HA 
gene function (Table 2; Supplementary Table 2). As shown in Fig. 4a, amino acid substitutions occurred 
within proximity of important functional domains of HA. Interestingly, two of these mutations may have 
an impact on antigenicity. Patient 328011 had a S545F residue alteration that occurred in a glycosylation 
site13; this mutation may have a significant impact on HA antigenicity13. Patient 35002 had a S80P substi-
tution that is adjacent to the Cb site that is within the vestigial esterase domain structurally determined 
by Xu et al.14. This mutation’s PROVEAN score (− 3.149) suggests a major impact on HA function.
Based on the analysis of the H3N2 results, five missense mutations were predicted to have a func-
tional impact (Table 3; Supplementary Table 3). Patient 302010 had a G240R substitution that directly 
Figure 4. Domain map of the HA gene with location of coding mutations. (a) The coding region of the 
H1N1 HA gene is shown as a vertical bar with colored protein domains as noted in the legend. Amino acid 
number is listed on the left side. All of the coding mutations are shown as black arrows. Coding mutations 
were aligned to previously described antigenic and glycosylation sites (20602265, 20339031)13,14. S545F 
was found in a previously identified glycosylation site. (b) The overall coding regions of the H3N2 HA 
gene is shown as a vertical bar with colored protein domains as per the legend15. Amino acid number is 
listed on the left side. All of the coding mutations [black arrows] and deletions [red arrows] were aligned 
to previously described H3 epitopes15. On the left of the domain and mutation map, the expanded coding 
mutations from Patient 328011 are shown on a linear MAF histogram plot. Of the eight mutations, P103S 
and G240R occurred in Epitope D and A304T occurred in Epitope C. One of the three deletions (C155) 
occurred in Epitope B.
www.nature.com/scientificreports/
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alters a H3N2 epitope15. This mutation may have a possible effect on antigenicity. There were a number 
of mutations that affected epitopes but did not have a significant Provean score. For example, Patient 
348020 had a mutation A304T substitution affecting Epitope C and Patient 317002 had a P103S substi-
tution that alters Epitope D15. Determining the functional consequences of these mutations will require 
further study.
Several deletions were identified in the H3N2 HA gene (Table 3). Patient 317002 had a three bp dele-
tion that was in frame and thus maintained the HA open reading frame. The functional consequences 
of in-frame mutations on HA gene function are unknown. For Patient 332005, a single base deletion 
occurred at HA nucleotide (nt) position 464. This leads to a frame shift in the HA gene and alters epitope 
B15. Patient 302004 had a five base deletion at HA nucleotide position 1527 and alters the frame past 
codon 509 which is proximal to the C-terminus.
To determine whether the mutations we identified had any overlap with antigenic drift from the 
2104/2015 influenza season, we conducted a review of the literature based on a PubMed search con-
ducted on 6/9/2015 with the following search terms: “2014 2015 influenza antigenic drift”; “H3N2 anti-
genic drift”; “H3N2 influenza A drift”; “2014 H3N2 drift”). We identified a study by Skowronski et al., 
that examined the presence of antigenic drift from the 2014/2015 influenza season for the H3N2 sub-
type16. We did identify a HA frameshift mutation at position 155 that is localized to the H3 cluster tran-
sition region and may be a key residue for receptor binding. Skowronski et al. identified HA mutations 
at positions 156 and 159 from the 2014/2015 season. Otherwise, there were no overlapping mutations. 
Given that there is a three-year interval between this study and ours and the small number of patients 
in our study, the lack of common mutations is not surprising.
Temporal changes in HA mutations during infection. One H1N1 and four H3N2 patients had 
longitudinal influenza samples with viral loads adequate for mutation detection at the 0.5% MAF thresh-
old (Table 4). We analyzed the sequence data as previously described and determined the MAF of the 
mutation for both time points (i.e. Time 1 and Time 2). For any given mutation, we calculated the fold 
change (FC) of the MAF between the two separate days. We employed a Z-statistic (Methods) to deter-
mine if the FC per a mutation was significant. Our analysis included a Bonferroni correction based on 
the overall length of the HA gene (e.g. approximately 1.7 Kb). All of the MAF longitudinal changes were 
found to be statistically significant (P < 0.0002) with the exception of two mutations that showed no 
significant MAF changes between the two time points.
Subtype
Patient 
ID
Day of 
Sample*
HA 
Gene Nt 
Position
Reference 
Nt
Variant 
Nt(s)
Mutation 
Allelic 
Fraction (%)
HA Amino 
Acid 
Position
Reference 
Amino 
Acid
Amino Acid 
Change Domain
Provean 
score
H1N1
325002 1 146 G A 1.35 49 G E − 4.208
326002 1 532 G A 0.64 178 V M adjacent to Ca site − 1.118
328011 1 697 T C 4.70 233 Y H adjacent to Ca site − 2.431
1372 A G 0.57 458 N D 1.423
1634 C T 0.58 545 S F glycosylation site − 3.184
335007 1 6 T G 21.63 2 N K 0.598
343011 1 1487 C T 0.65 496 A V − 2.353
350002 1 238 T C 1.84 80 S P adjacent to Cb site − 3.149
H3N2
302004 1 1430 G A 0.72 477 C Y − 7.835
1527 AGGGT -AGGGT 0.52 509 S frameshift  
302010 3 44 T C 9.57 15 L P − 4.512
718 G A 1.29 240 G R Epitope D − 4.130
1297 A G 7.87 433 N D − 3.566
1567 T C 61.10 523 S P − 2.903
302014 1 1469 T C 2.30 490 V A − 0.402
1 31 GCA -GCA 1.31 11 A in frame  
317002 307 C T 0.86 103 P S Epitope D − 0.805
3 31 GCA -GCA 1.28 11 A in frame  
332005 1 464 C -C 10.40 155 T frameshift Epitope B  
348020 1 910 G A 0.69 304 A T Epitope C − 0.386
Table 3. HA mutations leading to amino acid substitutions, deletions or frame shifts. *Day 1 is defined 
as the first day a sample was collected and was required to be collected within 48 hours of symptom onset.
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From these longitudinal samples, we identified a total of 16 mutations with a MAF of 0.5% or greater. 
Ten of these mutations lead to amino acid substitutions and the results are summarized in Table 4. The 
coding mutations leading to amino acid substitutions, deletions and frameshifts are mapped in the vicin-
ity of H3N2 HA domains (Fig. 4b). The remaining 14 mutations were above the 0.5% threshold at only 
a single time point, and underwent a significant MAF reduction during the course of infection. Among 
the five non-coding mutations in this set, four were detected at the first time point and saw reduced MAF 
at time point 2. One mutation was only detected at the second time point.
From the single H1N1 patient (328011), five mutations were identified at Day 1 with a MAF greater 
than 0.5%. On Day 3, all of these mutations dropped below the 0.5% MAF level. This included a synon-
ymous mutation at nucleotide position 1285; on Day 1 the MAF was 32.90% but subsequently dropped 
below 0.5%. The other mutations occurred at a MAF less than 5%, suggesting that there were different 
quasispecies present. The overall reduction in genetic diversity suggests that quasispecies were eliminated 
during the course of the 328011’s influenza infection and correlates with the drop in viral load that 
occurred between the two days.
For patient 30210, five HA mutations demonstrated an overall expansion between Days 1 and 3 
(Table 4 and Fig. 4b). All of these mutations had a MAF of less than 0.5% at Day 1 but expanded to as 
high as 61.10%. This includes four mutations that lead to amino acid substitutions. Among the expan-
sions was the G240R substitution that alters the H3N2 epitope D amino acid residue. Interestingly, the 
synonymous mutation demonstrated the smallest fold change compared to the mutations leading to 
amino acid substitutions. There was a slight increase in viral load between Days 1 and 3 (Table 1) where 
the log 10 viral loads went from 5.981 to 6.034. The increase in mutation MAF may represent random 
population drift or be the result of a selective advantage linked to antigenic changes. Interestingly, Patient 
30210 had an increase in viral load between the two time points.
Patient 302012 had a single mutation (e.g. nt position 489 A- > T) that did not alter the amino acid 
residue. This mutation had a MAF of 0.85% and was practically eliminated between Days 1 and 3.
Patient 302014 had two mutations. The first mutation (nt position 129 T- > C) was synonymous, did 
not lead to an amino acid substitution and remained stable in MAF during the two time points. The 
second mutation (nt position 1469 T- > C) leads to V490A residue change and showed a reduction in 
MAF below the 0.5% threshold. These results suggest the presence of at least two distinct quasispecies 
populations.
Patient 317002 had an in-frame three bp deletion that had a stable MAF from Days 1 and 3 with no 
statistically significant change. The other two alterations included a nonsynonymous (P103S substitution) 
and a synonymous mutation (nt position 1458 T- > C). The second mutation had an initial MAF less 
than 1.0% that was further reduced below the 0.5% MAF threshold. These results suggest that the qua-
sispecies populations can follow different trends in size during infection.
Subtype
Patient 
ID
HA 
Gene Nt 
Position
Reference 
Nt(s)
Variant 
Nt(s)
Time 1 
Mutation 
Allelic 
Fraction 
(%)
Time 2 
Mutation 
Allelic 
Fraction 
(%)
Fold 
Change 
(Time 1 
/ Time 
2)
HA 
Amino 
Acid 
Position
Reference 
Amino 
Acid
Amino Acid 
Change
H1N1 328011
519 A G 1.98 0.02 0.010 173 G None
697 T C 4.70 0.01 0.002 233 Y H
1285 T C 32.92 0.15 0.004 429 L None
1372 A G 0.57 0.01 0.021 458 N D
1634 C T 0.53 0.00 0.000 545 S F
H3N2
302010
44 T C 0.12 9.57 81.085 15 L P
718 G A 0.04 1.29 33.947 240 G R
1297 A G 0.09 7.87 91.558 433 N D
1567 T C 0.11 61.10 535.956 523 S P
1591 T C 0.05 1.23 27.289 531 L None
302012 489 A T 0.85 0.02 0.021 163 A None
302014
129 T C 4.09 6.77 1.654 43 V None
1469 T C 2.30 0.36 0.157 490 V A
317002
31 GCA -GCA 1.31 1.28 0.979 11 A Codon deletion
307 C T 0.86 0.18 0.206 103 P S
1458 T C 0.77 0.14 0.176 486 Y None
Table 4. Longitudinal analysis of HA mutations. Nt = nucleotide
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Discussion
We quantitatively detected HA mutations at a low fractional composition of the overall viral popula-
tion. Our study involved H1N1 and H3N2 influenza subtypes. This study demonstrates the presence 
and emergence of genetic diversity during active influenza infection. Recent studies such as Ghedin 
et al. showed that genetic diversity within individual influenza samples but few of these studies have 
examined mutation composition and longitudinal changes during active initial infection6. Overall, our 
study demonstrates the rapid emergence and fluctuations of novel mutations, an indicator of influenza 
quasispecies during active infection. Our results also suggest that antigenic drift is present relatively early 
during initial infection.
Among the eight coding point mutations that were predicted to be deleterious, the substitutions 
located adjacent to antigenic and glycosylation sites may alter the antigenic properties. Not surpris-
ingly, these mutations had not been noted in a previous survey of the influenza antigenic drift from the 
2014/2015 influenza season. Given that our small population was recruited from the 2011 season, the 
lack of overlap is not suprising.
To better define the role of novel HA mutations in antigenic drift will require additional character-
ization of these mutations from more samples. Future longitudinal studies of clinical populations will 
provide us with a better understanding of the functional significance of these novel mutations. Expanded 
deep sequencing of multiple influenza genes may help differentiate between background drift and drift 
related to host immune interactions. We are planning for such studies in the future. Overall, our results 
are supportive of the enormous potential for deep sequencing methods to provide additional insight 
about how the emergence of new influenza mutations impacts clinical outcomes.
Methods
H1N1 and H3N2 sample preparation. This study was conducted in compliance with the Helsinki 
Declaration and in accordance with approved experimental guidelines required by Stanford University. 
For all patients cited in this study, we obtained informed consent to conduct research. The study protocol 
and the experimental methodologies were approved by the Institutional Review Board (IRB) at Stanford 
University School of Medicine.
These individuals participated in a randomized, double blind, placebo-controlled phase 2B clinical 
trial and were in the placebo arm17. Individuals whose samples were analyzed in this study were enrolled 
in 8 different states (UT, CA, OK, FL, TX, OR, LA, CO, TN) across the United States17. It could not be 
confirmed whether any of the subjects could have been in contact with one another as a few subjects were 
enrolled in the same clinical centers but at different timeframes. The subjects were healthy individuals 
who presented with influenza-like illness (ILI) who later had laboratory confirmed influenza infection. 
Subjects were to be febrile with an oral temperature of ≥ 100 °F ( ≥ 37.8 °C) and have one or more ILI 
symptom (cough, sore throat, nasal symptoms, headache, myalgia, sweat/chills, or prostration). Samples 
were obtained at the time of presentation and this is listed as Day 1.
Nasopharyngeal samples were collected in viral transport media. Patients were confirmed to be the 
H1N1 or H3N2 influenza subtypes by quantitative PCR from these samples. The quantitative viral loads 
were determined (ViraCor-IBT, Lee’s Summit, MO)17. Viral load measurements (RNA copies/mL) were 
used to calculate the number of copies of influenza RNA per PCR amplification. The PCR target for 
each of the different subtypes of influenza A viruses was gene segment 4 (encodes for the hemagglutinin 
protein, HA). Our calculation considers the samples and the various aliquot volumes used for each step.
Consideration of viral copies for detecting mutations with sequencing. We identified samples 
for which the total number of viral copies was sufficient to accurately identify mutations at lower allelic 
fractions. Viral copies are derived from the viral load as measured with quantitative PCR. Thus, we can 
determine the number of template viral molecules that are used steps of the viral RNA and sequencing 
library preparation.
We determined a threshold for viral copies for our analysis. The MAF derived from sequencing cov-
erage data can be modeled as a binomial random variable with mean equal to (viral load)*(mutant allele 
frequency). Our estimate of the MAF is based on the proportion of reads at a site carrying the mutant 
allele (normalized to remove background sources of bias). The ratio of the standard error to mean of 
the mutant allele frequency estimate is approximately equivalent to 1/sqrt (viral copies per sequencing 
reaction * mutant allele fraction) for lower MAF values. For low viral copies used in a given HA gene 
PCR amplification, this ratio becomes increasingly large and points to the higher likelihood of spurious 
mutations introduced through amplification or sequencing. Thus, we restricted our analysis to those viral 
samples for which this ratio is larger than q for variants with mutation allele frequency less than r. The 
lower threshold on n should be 1/(rq^2). To achieve a value where r = 0.005 (MAF detection of 0.5%) 
and a q = 0.4, the threshold would be 100,000 viral copies per a PCR amplification.
Sequencing library preparation. From the viral media for the nasal swab, we used 140 μ l for 
RNA processing. Influenza RNA was extracted using Qiagen Viral RNA Mini Kits (Qiagen, Valencia, 
CA) in a total volume of 50 μ l eluent. From this RNA, we used 10 μ l of RNA for Superscript II RT 
reverse transcription with the primer Uni12 (Hoffmann, 2001) in a total volume of 20 μ l (Life 
Technologies, Grand Island, NY). Afterwards, 5 μ l of the cDNA was amplified using the Expand High 
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Fidelity PCR System (Roche Applied Sciences, Indianapolis, IN) and primer HANS-890R (Hoffmann) 
and primer HA-H3mw (AGCAAAAGCAGGGGATAATTC) for H3 samples, or primer HA-H1mw 
(AGCAAAAGCAGGGGAAAAC) for H1 samples. Cycling parameters were 1 cycle of 94 °C for 30 sec, 
40 cycles of 94 °C for 15 sec, 58 °C for 15 sec, 72 °C for 5 min, and 1 cycle of 72 °C for 10 min. The PCR 
products were purified using Qiagen PCR purification kits. Follow-up sample time points were chosen 
based on whether there was a sufficient amount of viral RNA for analysis.
Sequencing libraries were prepared from the H1 and H3 amplicons with the Nextera XT Sample Prep 
kit and Nextera XT 24 index kit (Illumina, San Diego, CA). A total of 3 ng of amplicon was incubated 
with the Nextera transposon enzyme for 1 minute at 55 °C. Subsequently, the sequencing library was 
amplified for 12 cycles, introducing multi-sample indexes and sequencing adapters as per the manu-
facturer’s protocol (Illumina). PCR parameters were 1 cycle of 72 °C for 3 minutes, 1 cycle of 95 °C for 
30 seconds, 12 cycles of 95 °C for 10 seconds, 55 °C for 30 seconds, 72 °C for 30 seconds, and 1 cycle of 
72 °C for 5 minutes after which samples were held at 10 °C. The PCR reaction was purified using 30 μ l 
(0.6 × volume) AMPure XP beads (Beckman Coulter) and eluted in 15 μ l elution buffer. Size profiles 
of libraries were analyzed with the Bioanalyzer High Sensitivity DNA assay (Agilent, Santa Clara, CA). 
The concentration of the sequencing libraries was determined by Qubit dsDNA HS assay (Invitrogen, 
Carlsbad, CA).
As described by Flaherty et al., our detection algorithm relies on high coverage sequence data gen-
erated from control gene amplicons in replicates8,9. We generated an independent set of HA control 
amplicons originating from a single, clonally derived plasmid with the HA gene. Sequencing the replicate 
HA amplicons enables us to determine the total experimental variance introduced by PCR amplification, 
the DNA sequencing library preparation and next generation sequencing with an Illumina system. The 
control amplicon sequencing occurs in the same sequencing run as the clinical samples.
To construct this plasmid, selected PCR products derived from influenza viral samples were cloned 
using TOPO TA cloning kits (Life Technologies, Grand Island, NY) per the manufacturer’s instruc-
tions and transformed into E. coli. We isolated individual clones of the transformed E. coli to insure 
clonal copy of the vector. Afterwards, an individual plasmid was subject to Sanger sequencing to con-
firm the HA gene sequence. With clonally-isolated plasmid as template, we used the same primers, PCR 
conditions and sequencing library method to generate at least three control replicate amplicons as the 
influenza clinical samples. As a final step, sample specific indexes were added to each of three libraries. 
Sequencing libraries were quantitated on both an Agilent Bioanalyzer and a fluorescent assay.
Deep sequencing of the HA gene, alignment and mutation analysis. The indexed sequencing 
libraries were pooled together in equal concentrations. This included libraries from the clinical sample 
HA gene and the control amplicon replicates that were run in triplicate to generate the error distribution 
necessary for variant calling. The indexed libraries were sequenced at a concentration of approximately 
10 pM on an Ilumina MiSeq with 150 by 150 paired-end reads using a V1 reagent cartridge (Illumina). 
The Illumina MiSeq software (MCS v2.0.5) performed read trimming to remove adapter sequence and 
binning of indexes to separate fastq files. Indexing assignment for sequence reads to the appropriate 
sample relied on the standard Illumina software.
All samples were aligned using the program BWA 0.6.2 with the default single-end sequence alignment 
parameters. For our references, we aligned the H1 samples, to the reference sequence RVDH1/2011_
H1N1 (Genbank KF848937.1) and the H3 samples were aligned to the RVD_H3/2011_H3N2 reference 
sequence (Genbank KF848938.1). Both reference sequences were approximately 1.7 Kb in length. The ref-
erence HA coordinates relied on the sequences provided by Soudararajan et al. for H12 and Wilson et al. 
for H318. The protein sequences of H1 and H3 controls were determined from the nucleotide sequences 
using fludb.org sequence annotation tool (http://www.fludb.org). The sequence data is available at the 
Short Read Archive (SRA) with the accession identifier SRP051062.
Analysis of HA mutations. After alignment, analysis for single nucleotide variants (SNVs) was 
conducted with the program RVD (http://dna-discovery.stanford.edu/software/rvd/)9. For the program’s 
parameters, we used sequence data with a base quality score of 30 or greater. We chose a minimum 
threshold of 0.5% MAF to call mutations which we previously demonstrated provides greater than 95% 
sensitivity and specificity when one achieves an average 2,000× sequencing coverage9. All mutations 
were visually confirmed with program IGV19. We only report mutations that were not found in the 
sequence data from the control amplicon replicates. After variant calling, we identified the nonsyn-
onymous mutations and determined the potential consequences of amino acid substitutions with the 
program PROVEAN using the default setting12. In the case of our analysis we used the default cutoff of 
− 2.5 to classify a neutral versus deleterious mutations.
We determined the majority consensus HA sequence. After RVD analysis, we identified the positions 
in the HA gene with a homozygous allele distinct from the reference sequence used for alignment. These 
homozygous positions were used to create a HA sequence consensus. We generated phylogenetic trees 
comparing the consensus nucleotide sequences of our clinical samples with those of the H1 and H3 ref-
erence sequences and the closest isolates by BLAST search as previously listed. For this analysis we used 
PhyML10,11 with default settings (http://www.fludb.org).
www.nature.com/scientificreports/
1 1Scientific RepoRts | 5:16178 | DOi: 10.1038/srep16178
For calling insertion and deletions (indels), we relied on the program Varscan220. For this analysis, 
we used the following settings: a minimum total sequencing coverage of 8 reads; a minimum number 
of variants seen in at least 2 non-duplicated reads; representation on both forward and reverse reads; a 
p-value of 0.05. The control amplicons were included in the indel analysis as well. Afterward, we vali-
dated the indel variants in the clinical samples with IGV and eliminated all indels that were also present 
in the three control amplicons.
Longitudinal comparison during viral infection. Five patients had two samples taken at two differ-
ent time points with adequate number of viral copies. These samples were used to determine longitudinal 
differences in the fractional representation of mutations for a specific patient. First, we identified the HA 
mutations with a 0.5% MAF or greater and compared it to the other time point. Given that many of 
the mutations from the secondary time point had a MAF lower than the 0.5% threshold, this required 
determining the actual read coverage of the mutation versus the read coverage for the reference base. As 
a secondary check, comparison to the amplicon controls data was also used to eliminate false positives.
To determine the statistical significance of MAF differences from two time points, we used the test of 
proportions (e.g. Z-test). For a given position, we considered the overall number of reads for a position 
and proportion of variant reads in Time 1 versus Time 2. We determined the read depth of the variant 
and wildtype allele for the mutation in question from each time point. The PROC FREQ procedure in 
SAS 9.2 (SAS Institute Inc, Cary NC) was used for this analysis and generated a p value fore each Z-score. 
Our significance threshold was P < 0.0000294 after the Bonferroni correction based on the overall bp 
length of the HA gene (1.6 Kb).
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